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Abstract 
EMPLOYING T CELLS FOR ANTIGEN PRESENTATION:  
ROLE OF NY-ESO-1+ T-APC VACCINE IN MULTIPLE MYELOMA 
 
Krina K. Patel MD MS 
Advisory Professor: Dean Lee MD PhD 
Introduction: Cellular therapy has shown great potential in early phase clinical trials 
with persistence of effector cells appearing to lead to improved outcomes. Combined 
immunotherapy with NY-ESO-1+ CAR T cells (TCR mimetic) and an NY-ESO-1 
specific T-APC vaccine in myeloma patients may lead to enhanced anti-myeloma 
efficacy due to improved persistence of the CAR T cells.  
Materials and Methods: Using the Sleeping Beauty transposon/transposase 
system, an NY-ESO-1+ TCR and CAR were created as effector cells. Vaccine was 
produced by electroporation of the NY-ESO-1 gene into T cells to make T cell 
antigen presenting cells (T-APC). Costimulatory molecules were added to the T-APC 
to help improve immunization efficacy. In vitro studies were conducted to evaluate 
the ability of T-APC to expand antigen specific effector cells compared to a positive 
control of K562 artificial antigen presenting cells (aAPC). The ability of effector cells 
(TCR versus CAR) to kill the U266 myeloma cell line and other targets was also 
evaluated. An MRD multiple myeloma mouse model using a U266 cell line was used 
to compare delayed tumor growth for CAR versus CAR+T-APC.  
 viii 
Results: NY-ESO-1+ T-APC with mIL-15 were successfully generated with >95% 
expression of the antigen and co-stimulatory molecule. In vitro studies confirmed the 
NY-ESO-1+ CAR expanded upon co-culture with T-APC and lysed the U266 line 
more efficiently than the NY-ESO-1+ TCR.  Subsequent in vivo studies revealed the 
NY-ESO-1 CAR delayed tumor growth significantly when compared to the control 
tumor only group and irrelevant CAR control CD19R+ CAR group. The NY-ESO-1+ 
CAR + T-APC group showed similar tumor delay using bioluminescent imaging, but 
improved tumor control on necropsy compared to the NY-ESO-1+ CAR alone group. 
The NY-ESO-1+ CAR + T-APC group also showed increased persistence of CAR+ T 
cells with memory phenotype compared to all other experimental cohorts.  
Conclusion: NY-ESO-1+ T-APC work similarly to K562 aAPC in expanding NY-
ESO-1+ CAR T cells in vitro, and lead to improved persistence of CAR T cells and 
anti-myeloma effect in vivo.  
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CHAPTER 1: Introduction 
Combination immunotherapy with CAR T cells and T-APC vaccine post 
autologous transplantation (auto-HSCT) has great potential for improving outcomes 
in patients with high risk multiple myeloma (MM). Auto-HSCT alone for MM leads to 
transient complete responses and extended progression-free survival in a subset 
(20-30%) of patients.1-3 Even after tandem HSCT, relapse is inevitable in the 
majority of cases.4 Patients with high-risk disease (defined as deletion 17p, t[14;16], 
or t[14;20]), have an overall survival of 18 to 36 months.  Allogeneic HSCT may 
increase the rate of cure through T cell-mediated graft-versus-MM effect, but 
conveys increased risk of morbidity and mortality from graft-versus-host disease. 
After auto-HSCT, decreased anti-tumor immunity leads to suboptimal control of 
minimal residual disease (MRD) and eventual progression. Furthermore, after high-
dose chemotherapy, decreased lymphocyte number and function can last for months 
to years.5 Alternatively, robust recovery of lymphocyte counts predicts improved 
survival for MM after auto-HSCT, through augmentation of the host antitumor 
immunity.6,7    
Adoptive T cell therapy with antigen specific effector T cells targeting the 
tumor-associated antigen (TAA) NY-ESO-1 in the context of HLA has great potential 
for treatment of multiple myeloma.  However, persistence of similar effector cells 
post transplantation in other malignancies is variable. Therefore, the addition of NY-
ESO-1+ T antigen presenting cell (T-APC) vaccine is a novel approach to improve 
the persistence of adoptively transferred T cells post autologous transplant as well 
 xii 
as improve endogenous long-term immunity through both direct and cross-priming 
as described in Figure 1.  
 
Cancer vaccines have resulted in some clinical responses, but have fallen 
short of their potential.8,9 Current vaccine strategy shortcomings include difficulty 
with optimal antigen delivery by professional antigen-presenting cells (APCs), 
requirement for costimulatory molecules, difficulty with manipulating and expanding 
Figure 1. Mechanism of antigen presentation for generation of T-cell immune response. 
Plasmid DNA is electroporated into the T-APC, processed intracellulary, and presented to an 
effector T cell in an MHC restricted manner through direct priming. Concurrently, cross 
presentation of the antigen from the T-APC to professional antigen presenting cells, such as 
dendritic cells, followed by direct priming may lead to an increased generation of antigen 
specific T cells.     Courtesy of Simon Olivares 
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professional APCs in vitro, and ineffective delivery to tumor sites.10 The ability to 
propagate and genetically modify T cells may help overcome limitations of 
translating professional APC into T-cell vaccines. Activating T cells ex vivo can lead 
to up-regulation of HLA class I and II, and co-stimulatory molecules, such as CD80 
and CD86. Furthermore, endogenous T-cell responses have been observed in 
patients to transgenes expressed by genetically modified T cells which suggest the 
ability of T cells to function as APC.11 This new approach will augment immunity 
against tumor cells by combining adoptive transfer of CAR T cells with the co-
administration of a T-cell based vaccine where T cells act as APC (T-APC). T cells 
and other vaccines have been co-administered to MM patients to improve immunity 
after auto-HSCT and achieved responses to pneumococcal vaccine and a multi-
peptide vaccine including human telomerase reverse transcriptase (hTERT) and 
survivin.12,13 In these early clinical studies, in vivo vaccine-primed and ex vivo 
propagated effector T cells were infused during a period of lymphopenia followed by 
vaccine boost. Therefore we hypothesized that T-APC would expand antigen 
specific effector cells and lead to improved killing of myeloma, both in vitro and in 
vivo. If this approach is deemed successful, translation to anti-myeloma therapy has 
great potential to improve life for our patients.  
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Figure 2.  (A) TCRs comprise α/β heterodimers that bind to peptide in a major 
histocompatibility complex (MHC) restricted manner. TCRs complex with CD3 
subunits and co-receptors (CD4 or CD8) associated with Lymphocyte-specific 
protein tyrosine kinase (Lck). CARs contain single-chain variable fragment (scFv) 
recognition domains capable of binding to cell surface antigens.  CARs contain 
intracellular signaling domains from CD3ζ and a co-stimulatory molecule (typically 
CD28 or 4-1BB). Signaling is initiated by Lck-mediated phosphorylation of immuno-
tyrosine activation motifs (ITAMs) within the cytoplasmic domains of CD3. (B) APC 
can engage and expand T cells through TCR or CAR. Courtesy of Simon Olivares 
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CHAPTER 2: Materials and Methods 
Ethics Statement. All research involving human samples was in accordance with 
protocols established and approved by the MD Anderson Cancer Center Internal 
Review Board (IRB). Animals treated in this study were handled in accordance with 
the strict guidelines established by the MD Anderson Cancer Center Institutional 
Animal Care and Use Committee (IACUC). Mice were housed in pathogen-free 
conditions and were monitored daily for welfare-related assessments in accordance 
to IACUC guidelines.  
DNA plasmids 
Generation of NY-ESO-1 expression plasmid for T-APC. The sequence for the 
NY-ESO-1, also known as CTAG1A (GenBank: AJ003149.1), gene was triple flag 
tagged at the 5’ -end and linked to a hygromycin phosphotransferase (Hygro) gene 
by a foot-and-mouth disease virus 2A self-cleavable peptide.  The flag-NY-ESO-1 
fusion gene was human codon optimized and synthesized by GeneArt (Germany), 
and cloned into vector Flag-RhCMVpp65 (CoOp)-F2A-HA-Hyg/pT2SBSO using 
restriction enzymes ClaI and AfeI at 5’ -end and 3’ -end respectively.  This cloning 
generated the Sleeping Beauty plasmid Flag-NY-ESO-1 (CoOp)-F2A-HA-
Hyg/pT2SBSO, which constitutively expresses the fusion gene under the control of 
the hEF-1α promoter. 
Generation of NY-ESO-1 specific TCR expression plasmid.  The 1G4 TCRαβ 
sequence was obtained from Robins et al (14).  The sequence was codon optimized 
and synthesized by GeneArt (Germany).  The 1G4 TCRαβ cassette was cloned into 
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vector GlySer-EGFP (CoOp)/pT2SBSO using restriction enzymes NheI and XhoI at 
5’ –end and 3’ –end respectively.  This generated the final sleeping beauty 
transposon plasmid Anti-NY-ESO-1 TCRs (CoOp)/pT2SBSO, which constitutively 
expresses the TCRαβ under the control of the hEF-1α promoter.   
Generation of NYESO1-CD28 CAR (TCR mimetic) transposons. The CARs 
NYESO1-IgG4-CD28 and NYESO1-CD8α-CD28, were constructed using the Fab 
antibody-fragment T1, previously described (15), which binds to the HLA-A2/NY-
ESO-1(peptide 157-165) complex.  The scFv sequence was comprised of the VH and VL 
sequences of the Fab antibody-fragment T1, along with a Kozak consensus 
ribosome binding sequence and the human GM-CSF receptor alpha-chain leader 
peptide. The VL was connected to VH using the Whitlow linker peptide (amino acid, 
GSTSGSGKPGSGEGSTKG).  The scFv was further connected in frame to the hinge 
and transmembrane regions of the human CD8α chain (residues 115 – 189 of the 
mature protein), or to a modified human IgG4 hinge and Fc regions (residues 161 – 
389 of the mature protein), and a CD28 transmembrane domain.  The hinge on the 
Fc, was mutated from amino acids CPSC and CPPC (single letter code) to enhance 
stability of the dimerized IgG4 heavy chain. The transmembrane regions were fuse in 
frame to the CD28 endodomain which was connected in frame to the CD3- 
cytoplasmic domain.  Both CARs were codon optimized and synthesized by GeneArt 
(Germany), and cloned into the clinical sleeping beauty plasmid CD19R-CD8a-CD28 
(CoOp)/pSBSO-SIM using restriction enzymes NheI and XhoI at 5’ -end and 3’ –end 
respectively.  This procedure generated the two CAR plasmids NY-ESO-1R- CD8α-
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CD28 (CoOp)/pSBSO-SIM and NY-ESO-1R-IgG4-CD28 (CoOp)/pSBSO-SIM, which 
constitutively express the CAR under the control of the hEF-1α promoter. 
SB11 Plasmid 
The SB transposase SB11 was expressed from plasmid pCMV-SB11 as previously 
described.16 
Membrane bound IL-15 (mIL15) 
IL-15 fused to IL-15Rα (membrane bound) was constructed as previously 
described.17,18 
Electrotransfer of plasmid vectors 
Generation of T-APC 
To manufacture T-APC’s, normal donor human PBMC’s were genetically modified 
by electroporation using the Sleeping beauty system as previously described16. 
Briefly, PBMCs were thawed, washed and rested for 2-4 hours. They were then 
resuspended in hypo-osmolar buffer at 100x10^6 cells/mL. Aliquots were added to 
0.2 cm cuvettes containing 15µg of the NY-ESO-1/HLAA2 plasmid, 15 µg of the IL-
15 plasmid, 5µg of CRISPR-Cas9-Lag3 plasmid (CRISPR-Cas9 based plasmid 
specific for Lag3, GenBank: NM_002286, gene targeting at exon 2. This was a kind 
gift from Dr. Aleksandra K Nowicka), and 10µg of sleeping beauty transposase SB11 
plasmid, in a total volume of 400 µL. Each cuvette received a single 40-microsecond 
pulse of 250V after which the cells were rested in 20% FBS phenol free RPMI  
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overnight. The next day, the cells were co-cultured with OKT3 aAPC (K562 aAPC 
loaded with anti-CD3 antibody, OKT3, via CD64 Fc receptor) and IL-21. Cytocidal 
levels of hygromycin at 0.2 µg/mL were added on day +5 and subsequently weekly.    
Generation of K562 aAPC 
K562 artificial antigen presenting cells, K562-A2+ NY-ESO-1 aAPC , was generated 
though enforced co-expression of truncated CD19, CD64, CD86, CD137L and HLA-
A2 on K562 cells genetically modified with lentiviral vectors and was a gift from Carl 
June (University of Pennsylvania)19. This aAPC was further modified using SB 
system to co-express the Flag-NY-ESO-1-F2A-HA-Hygro fusion protein, the cells 
were grown in cytocidal levels of hygromycin at 0.4 µg/mL, to eliminate the non-
integrants, and to enforce the expression of the NY-ESO-1 protein. The K562-A2+ 
NY-ESO-1  aAPC uniformly and stably co-expressed CD19, CD32, CD64, CD86, 
CD137L, HLA-A2 and NY-ESO-1 (detected by intracellular flag staining).  
Generation of NYESO-1 TCR and NYESO-1 CAR T cells1G4 TCR+ and CAR+ T 
cells were propagated based on modifying standard operating protocols as 
previously described20,21. Cryopreserved PBMC, obtained from healthy donors after 
informed consent, were thawed the day of the electroporation (designated day 0) 
and rested for 2 hours at 37°C. PBMC for electroporation were spun at 200g for 10 
minutes and 10x106 cells were mixed with supercoiled DNA plasmids (2.5 μg SB11 
transposase and 7.5 μg SB transposon) in Human T cell Nucleofector Solution 
(cat#VPA-1002, Lonza), added to a cuvette, and electroporated on the U-014 
program of Amaxa Nucleofector II (Lonza). Electroporated cells were transferred to a 
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6-well plate containing phenol-free RPMI, 20% FBS, and 1x Glutamax-100. The 
following day, electroporated T cells were phenotyped and stimulated with either 
irradiated (30Gy) NY-ESO-1 T-APC or irradiated (100Gy) K562-A2+ NY-ESO-1 
aAPC at a ratio of 1:1 (CAR or TCR+ T cell : aAPC). Each co-culture was 
supplemented with IL-21 (cat# AF20021; Peprotech, Rocky Hill, NJ; 30 ng/mL) 
starting at initiation of culture and every 2–3 days thereafter. TCR and CAR 
expression was evaluated weekly to determine the number of aAPC to add to co-
cultures every 7 days. If contaminating NK cells reached >10% of the total 
population, they were depleted from co-cultures with paramagnetic CD56 
microbeads (Miltenyi Biotec, Auburn, CA) and LS columns (Miltenyi Biotec). 
Phenotyping and functional analyses were performed between days 21 to 29.  
Cell lines. K562, EL4 and U266 cell lines were acquired from American Type 
Culture Collection (Manassas, VA), and were maintained in complete media (RPMI, 
10% FBS (Hyclone, Logan, UT), and 1x Glutamax-100). All tumor cells were free of 
mycoplasma and other microbial pathogens. 
Flow cytometry. All mAbs were purchased from BD Biosciences (San Jose, CA), 
except for CCR7 mAb (eBioscience, San Diego, CA), IL-15 mAb (R&D Systems, 
Minneapolis, MN), Fc mAb used to detect CAR (Invitrogen), and R-PE labeled Pro5 
MHC Pentamer NY-ESO-1,  (ProImmune). Staining was performed as described22. 
Samples for flow cytometry were acquired on FACS Calibur (BD Biosciences) and 
analyzed using FCS Express  (version 3.00.0612). 
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In vitro cytoxicity and cytokine production. In vitro specific lysis was assessed 
using a standard 4-hour chromium release assay, as previously described21. 
Expression of cytokines was evaluated by intracellular staining and flow cytometry. 
CAR+ T cells were incubated with an equal volume and number of target cells for 6 
hours at 37°C in the presence of Brefeldin-A (GolgiPlug; BD Biosciences) to block 
exocytosis and secretion of cytokines. Co-cultures were then (i) stained for surface 
markers, e.g., CD3 and CAR , (ii) fixed and permeabilized with BD Cytofix/Cytoperm 
(cat# 555028, BD Biosciences), (iii) stained for intracellular IFNγ, and (iv) analyzed 
by flow cytometry. Positive control were T cells treated with Leukocyte Activation 
Cocktail (BD Biosciences). 
Mouse In Vivo Model. U266-ffLuc-EGFP tumor cells were generated by 
electroporating U266 cells during log phase growth with linearized ffLuc-EGFO-
pcDNA. Transduced U266 myeloma cells were sorted for uniform EGFP expression 
by FACS to obtain cells with ffLuc activity suitable for non-invasive BLI. 
Immunocompromised female NSG mice (6–12 weeks of age; NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ; Jackson Laboratory, Bar Harbor, ME) were intravenously (i.v.) 
injected with 1.25x104 U266-ffLuc-EGFP cells on day 0 (total n = 30), were mixed 
together, and then randomly distributed into 6 groups, which were treated with (i) no 
treatment (n = 5), (ii) NYESO1CD28+ CAR T cells (n = 5),  (iii) NYESO1CD28+ CAR 
T cells + NYESO1 T-APC (n = 5), (iv)  CD19RCD28+ CAR T cells, (v) CD19RCD28+ 
CAR T cells + NYESO1CD28+ CAR T cells, and (vi) NYESO1 T-APC alone. CAR T-
cell doses (107 total cells per mouse) were administered on day 1 while T-APC 
doses (107) were infused on days 1 and 5 for group 3 and 5. CAR expression on 
 xxi 
infused T cells was 89% for the NYESO1CD28+ CAR and 90% for the CD19CD28+ 
CAR.  The T-APC flag expression was 80% on day of infusion. BLI from tumor ffLuc 
was monitored weekly. Student t test [1 tailed, type 2] was used for statistical 
analysis between groups of mice (n = 5 per group). At the end of the experiment, 
mice tissue (blood, spleen and bone marrow) was harvested and analyzed for the 
presence of tumor (GFP) and T cells (CD3). 
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CHAPTER 3: Results 
 
NY-ESO-1 T-APC were successfully constructed with the NY-ESO-1 and 
IL-15 co-stimulatory molecule plasmids. It has been previously shown that T cells 
increase expression of CD80 and CD86 (co-stimulatory molecules also on 
professional antigen presenting cells) upon activation11. However, to increase the T-
APC potency, several costimulatory adjuvants were evaluated. IL-15 regulates T and 
NK cell activation and proliferation, provides survival signals to maintain memory T 
cells in the absence of antigen, and suppresses apoptosis in T cells by inducing Bcl-
2 and Bcl-xL23-25. CD40L, a member of the TNF superfamily, augments anti-cancer T 
cell immune responses by triggering effective activation and maturation26. IL-7 is 
important for B and T cell development and homeostasis and may decrease 
CD4+CD25+Foxp3+ regulatory T cells27.  The goal was to find the best combinations 
of co-stimulatory molecules added to the T-APC which would lead to increased 
immunogenicity. Even though mIL-15 was successfully electroporated into the T-
APC, unfortunately the CD40L and IL-7 plasmids failed to integrate for unknown 
reasons despite multiple attempts. Therefore, the rest of the studies were continued 
with IL-15 alone as an adjuvant for the T-APC. As shown in Figure 3, T-APC 
successfully expressed both the NY-ESO-1 (flag) antigen on intracellular staining as 
well mIL-15 on surface staining. There are no commercially available flow antibodies 
for cancer testes antigens like NY-ESO-1, therefore a flag was added to the plasmid 
for which intracellular staining could be done to confirm integration. Furthermore, 
because this antigen is MHC restricted, HLA-A2+ T cells were used for the study.  T-
APC are expanded on OKT3 aAPC; when comparing T- APC with no co-stimulatory 
 xxiii 
molecules to T-APC with mIL-15, the latter expanded slightly better, but this was not 
significant (Figure 4). 
 
 
 
Figure 3. T-APC Phenotype. 
T-APC were electroporated 
with mIL-15 and NYESO1 
antigen and cultured on OKT3 
aAPC. After 4 weeks of 
stimulations, T-APC had 
greater than 90% Flag+ 
(intracellular stain for 
detection of the NY-ESO-1) 
and IL-15 (surface stain) 
expression. 
Figure 4. T-APC Expansion 
Kinetics. T-APC were expanded on 
OKT3 aAPC in the presence of IL-21. 
T-APC without mIL-15 also had IL-2 
added to the culture. T-APC with 
mIL-15 had a trend towards 
increased expansion compared to T-
APC with no costimulatory 
molecules, however it was not 
significant (p value 0.3, 2 way 
ANOVA). 
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The T-APC were able to propagate the NY-ESO-1 CAR as well as the NY-ESO-1 
K562 aAPC, in vitro. K562 aAPC have been used to expand CAR T cells and TCR+ 
T cells by our group16. Therefore, experiments were conducted comparing the ability 
of the NY-ESO-1 T-APC (experimental) versus the K562 aAPC to expand antigen 
specific effector T cells. These effector T cells included NY-ESO-1+ CAR T cells 
(TCR mimetic), NY-ESO-1+ TCR T cell and non-modified T cells to evaluate both 
APC types’ ability to truly vaccinate in an antigen specific manner.  Figure 5A 
demonstrates that T-APC is able to induce NY-ESO-1 specificity in TCR+ and non-
modified T cells by day 14. However as shown in Figures 5B and 6, TCR+ T cells 
and non-modified T cells do not expand in the presence of T-APC. TCR+ T cells 
expand with K562 aAPC, however non-modified T cells do not expand with either 
APC. NY-ESO-1+ CAR T cells however expand with both T-APC and K562 in a 
comparable manner.  
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Figure 5. Expansion of effector cells (CAR, TCR, PBMCs) on T-APC versus K-
562 aAPC.  Unmodified PBMCs or PBMCs electroporated with NYESO-1 
CAR/NYESO-1 TCR were co-cultured on T-APC or K562 aAPC expressing the 
NYESO-1 antigen and evaluated for TCR/CAR expression using NYESO1 
pentamer. The TCR and PBMC had increased NY-ESO-1 expression at day 14 with 
the T-APC (A), however, not as well as compared to the CAR T cells when 
cultured for 28 days(B).  T-APC expanded the CAR just as well as the K562 aAPC 
(positive control). 
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To evaluate specificity of the NY-ESO-1 T-APC, a soluble form of NY-ESO-1 
CAR was produced and conjugated to PE-Cy5 (Creative Biolabs) for flow cytometric 
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Figure 6.  Expansion kinetics for CAR/TCR+ Tcells. Unmodified or, CAR+/TCR+  T 
cells were co-cultured on K562 aAPC or T-APC and enumerated every week to 
evaluate their proliferation. (A)Non-modified T cells (No DNA CD3+ T cells) do not 
expand with either K562 aAPC or T-APC. NY-ESO-1+ TCR expand well with the 
K562 aAPC, but not the T-APC. (B)The CAR T cells expand just as well on K562 
aAPC (shown) and T-APC (data not shown).  
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detection of NYESO-1 antigen on APCs and tumor cells. As in figure 7, testing 
showed background expression of 3.7% on control T cells. The T-APC had a 
surprisingly low 13.8% expression while the U266 myeloma cell line, known to have 
high levels of NY-ESO-1 expression by IHC, showed 57% binding to the soluble 
CAR. T-APC from only one donor was tested and it had only 79% expression of flag.  
 Due to the lack of expansion of the NY-ESO-1 TCR+ and non-modified T 
cells by the NY-ESO-1 T-APC, both co-stimulatory and inhibitory molecules were 
checked on the T-APC prior to each stimulation. The NY-ESO-1 T-APC had fewer 
co-stimulatory molecules and more inhibitory molecules expressed compared to the 
NY-ESO-1 K562 aAPC (figures 8 and 9). This surprisingly revealed that T-APC, 
which are expanded on OKT3 aAPC, had increasing levels of LAG3 with each 
expansion and decreased expression of most other co-stimulatory molecules, 
contrary to previous data11.  
Figure 7. NY-ESO-1 Expression. An NY-ESO-1 HLA-A2 soluble CAR linked to (PE-
Cy5) was obtained from (Creative Biolabs). Unmodified T cells, T-APC and U266 
cells were stained with soluble CAR for 30 min and analyzed using flow cytometry.  
NY-ESO-1 T-APC expressed __ 10% more than the negative control of non-modified 
T cells. The positive control, the U266 cell line, demonstrated 57% expression. 
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Figure 9. Inhibitory molecules expressed by T-APC. Expression of PD1, PDL1, TIM3 
and LAG3 was measured after 7 days of culture by flow cytometry. Increased 
expression of LAG3 was observed with each stimulation of T-APC with OKT3 aAPC.  
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Figure 8.  Co-stimulatory molecules expressed on (top) T-APC and (bottom) 
K562.  T-APC showed minimal levels of CD28 and high levels of CD54, while the K562 
aAPC expressed CD137L, CD86, CD64, and CD32.  
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LAG3 is known to bind to MHC II with higher affinity than CD4 and negatively 
regulate cellular proliferation, activation and homeostasis of T cells28,29. It also helps 
maintain CD8+ T cells in a tolerogenic state. Therefore the next set of experiments 
evaluated the effects of inhibiting LAG3. Experiments were initially conducted using 
a LAG3 monoclonal antibody which was added to the T-APC and TCR cultures; 
however all the cell cultures died after 2 weeks. Because the monoclonal antibody 
was cumbersome and expensive, a LAG3 knockout (KO) version of the T-APC was 
created utilizing the CRISPR-Cas9 system30. Experiments using the LAG3 KO 
versus wild type (WT) T-APC were conducted to evaluate effector cell expansion 
capabilities. Although initially a difference was seen, after 3 weeks of co-culture, all  
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Figure 10. Redirected lysis of CAR/TCR T cells using chromium release 
assay.  The U266 cell line was co-incubated with different effector cells 
including non-modified T cells (CARneg), NY-ESO-1+ TCR, NY-ESO-1+ CAR with 
the IgG stalk, and NY-ESO-1+ CAR with CD8α stalk. The NY-ESO-1 CAR with 
CD8α stalk killed the U266 cell line most. 
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cells died off and no conclusions could be inferred. Evaluation of LAG3 KO versus 
WT did reveal decreased IL-2 and increased IL-10 production in the WT group (data 
not shown). These studies will need to be repeated in the future. 
All NY-ESO-1 specific effector cells were able to kill the U266 myeloma cell 
line better than non-specific T cells, however the CD8alpha CAR demonstrated the 
most efficient in vitro killing. Due to increased immunogenicity, non-specific 
activation and clearance via binding to Fc receptors of CARs containg the IgG4 
stalk we switched to a CD8α stalk for all CAR T cells. Therefore, we repeated the 
chromium release assay shown in figure 10, which demonstrated improved 
cytotoxicity by the new CD8 NYESO-1 CAR compared to the IgG CAR.  
Owing to superior expansion on NY-ESO-1 T-APC and improved lytic 
capabilities of the NY-ESO-1+ CAR with CD8α stalk, an in vivo experiment with this 
combination was performed.  
 Five cohorts were studied in this minimal residual disease model in vivo 
experiment: tumor only, NY-ESO-1+ CAR, NY-ESO-1+ CAR and T-APC, CD19R 
CAR, CD19R CAR and NY-ESO-1+ CAR, and T-APC alone. Tumor cells were given 
on day -1, followed by CAR T cells +/- T-APC on day 0. Repeat T-APC were given to 
the two groups getting vaccine on day +5 as a boost (Figure 11). Mice were imaged 
weekly and sacrificed on day +43 for T cell and tumor evaluation (Figure 12). Any 
group of mice that received the NY-ESO-1+ CAR, had the most delayed tumor 
growth. Interestingly, the only cohort that had CAR still persistent at time of sacrifice, 
 xxxi 
were the mice that received NY-ESO-1+ CAR and T-APC. Further investigation 
revealed that some of the persisting CAR T cells had memory phenotype as well.  
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Figure 11.  In vivo MRD mouse model.  Six groups of mice (n=5 per group) 
were injected with tumor on day -1 followed by CAR T cell injections on day 0.  
Two groups of mice had T-APC injected at day 0 and day +5. The six groups 
were tumor only, tumor + NY-ESO-1+ CAR, tumor + NY-ESO-1+ CAR + NY-ESO-
1 T-APC, tumor + NY-ESO-1+ CAR + CD19R+ CAR, tumor + CD19+ CAR, and 
tumor + NY-ESO-1 T-APC.  89% of NY-ESO-1+ CAR T cells were NY-ESO-1 
pentamer positive on day 24, which was day of infusion.  
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Table 1. Summary of Tumor and T cells in mice at days 43-45.   
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CHAPTER 4: Discussion 
 Despite the surge of FDA approved novel therapies for multiple myeloma 
patients in recent years, the disease is still considered largely incurable. However, 
with more patients reaching a minimal residual type state, introducing 
immunotherapy at this point (i.e. post autologous stem cell transplant) may be our 
best hope to lead to cure. Cell therapy has shown great potential in CD19+ diseases 
such as acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphomas 
(DLBCL), but studies in myeloma patients are very early. Longer persistence of 
these cells seems to be associated with improved outcomes. Therefore, using a 
vaccine such as T-APC which is easy to make and manipulate, inexpensive, and 
easy to give, in conjunction with CAR T cells, may lead to improved persistence and 
therefore outcomes.  
 Because NY-ESO-1 is an intracellular antigen which needs to processed and 
presented in an MHC restricted manner, we were limited to testing our hypothesis in 
HLA-A2+ donors. The T-APC were easily produced with >90% Flag and IL-15 
expression with most donors; however, two major issues still remain: (1)  we have 
not been able to show specificity of the T-APC and (2) we were unable to add any 
other co-stimulatory molecules besides IL-15, to help improve function. We also 
were not able to show an increase in CD80 or CD86 co-stimulatory molecules with 
the activation of the T-APC as our previous study had shown.  
 Our effector T cell studies showed that the T-APC with IL-15 were able to 
produce NY-ESO-1 specific T cells from un-manipulated PBMC while NY-ESO-1 
 xxxvi 
K562 aAPC were not able to do so. However, the T-APC could not expand these 
effector cells or the NY-ESO-1+ TCR cells numerically. The NY-ESO-1+ CAR T cells  
(TCR mimetic) expanded in an antigen specific manner with both the T-APC and 
K562 aAPC. Furthermore, the NY-ESO-1+ CAR T cells killed the greatest 
percentage of the U266 myeloma cell line in vitro. Thus, the CAR T cell and T-APC 
combination was taken forward.  
 In our MRD in vivo model, we demonstrated that the mice which received the 
NY-ESO-1 CAR T cells (tumor + NY-ESO-1+ CAR T cells, tumor + NY-ESO-1+ CAR 
T cells + NY-ESP-1 T-APC, and NY-ESO-1+ CAR T cells + CD19R+ CAR T cells) 
had the lowest tumor burden when all the mice were sacrificed between days 43-45. 
The T cells persisted only in the two groups which received T-APC and in the group 
which received the NY-ESO-1 CAR and CD19R CAR. The group which received 
NY-ESO-1+ CAR T cells and T-APC had the most effector T cells present at time of 
sacrifice with the lowest tumor burden on necropsy. The CAR T cells had the 
greatest distribution of subtypes as well, from naïve to memory to effector T cells.  
 As seen in our in vivo studies, we would predict that giving T-APC and CAR T 
cells to myeloma patients would lead to persistence of effector cells of memory and 
effector subtypes along with decreased tumor burden than giving CAR T cells alone. 
We hope that this will translate into longer progression free survival and overall 
survival for our patients.  
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CHAPTER 5: Limitations 
 
This study has a novel approach for improving CAR T cell persistence and 
potentially providing an alternate vehicle for anti-cancer vaccines. More studies need 
to be conducted, however, to prove this.  
The biggest limitation to this study is lack of true specificity of the T-APC. The 
NY-ESO-1 antigen unfortunately does not have a commercially available antibody 
which we could use to detect its expression on the T-APC. We therefore purchased 
a soluble NY-ESO-1+ CAR (TCR mimetic) attached to a known flow color. 
Unfortunately we only tested this on one donor T-APC which was only 79% flag 
positive at that time. The soluble CAR seems to work with negative control showing 
background expression of 3.8% and positive control (U266 myeloma cell line) 
showing 57% expression.  
Further limitations include the MHC restricted status of this antigen. Further 
work is being done in our lab to make “off the shelf” cell therapy products for this 
antigen as well as other cancer testis antigens.  
IL-15 has the potential to be leukemogenic. Therefore switch technology is 
being developed to be able to turn IL-15 on T-APC off if need be.  
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CHAPTER 6: Future directions 
We are currently completing in vivo mouse survival studies to further 
investigate the clinical translational potential of NY-ESO-1+ CAR and T-APC versus 
NY-ESO-1+ CAR alone.  
We will also thaw our previous 4 T-APC products from different donors and 
repeat flow evaluation with the NY-ESO-1+ soluble CAR to test specificity. We will 
also re-evaluate the expression of other co-stimulatory molecules such as CD80 and 
CD86 on all these donor T-APCs with new antibodies.  
We will attempt to increase immunogenicity of the T-APC with the addition of 
CD40L +/- IL-12 with new plasmids. 
Finally we hope to conduct a phase I/II clinical trial using NY-ESO-1+ TCR 
mimetic with T-APC in patients with multiple myeloma.  
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